Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PTC Therapeutics (PTCT – Research Report), ...

In a report released yesterday, Joseph Schwartz from Leerink Partners maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that Health Canada has authorized Vabysmo® ...

Equities research analysts at Cantor Fitzgerald increased their FY2024 earnings estimates for PTC Therapeutics in a report ...

Gabrielle White has been appointed as president of the Irish Exporters Association, the organisation said on Thursday. She ...

Orsini announced today that it has been chosen by PTC Therapeutics as the exclusive specialty pharmacy provider for the adeno-associated virus vector-based gene therapy KEBILIDItm (eladocagene ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...